Caroline E Morton
A5037645558- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Vaccine Coverage and Hesitancy
- Chronic Disease Management Strategies
- COVID-19 epidemiological studies
- Healthcare cost, quality, practices
- Climate Change and Health Impacts
- COVID-19 and Mental Health
- Venous Thromboembolism Diagnosis and Management
- Health disparities and outcomes
- Atrial Fibrillation Management and Outcomes
- Influenza Virus Research Studies
- Intensive Care Unit Cognitive Disorders
- Frailty in Older Adults
- Scientific Computing and Data Management
- Machine Learning in Healthcare
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Research Data Management Practices
- Genetic Associations and Epidemiology
- Geriatric Care and Nursing Homes
- COVID-19 Impact on Reproduction
- Obesity and Health Practices
- Respiratory Support and Mechanisms
Queen Mary University of London
2023-2025
University of Oxford
2019-2024
Nuffield Health
2021-2024
Bennett University
2023
London School of Hygiene & Tropical Medicine
2019-2023
Wellcome Trust
2023
Medical Research Council
2023
UK Research and Innovation
2023
Health Data Research UK
2023
William Harvey Research Institute
2023
Abstract Background Establishing who is at risk from a novel rapidly arising cause of death, and why, requires new approach to epidemiological research with very large datasets timely data. Working on behalf NHS England we therefore set out deliver secure pseudonymised analytics platform inside the data centre major primary care electronic health records vendor establishing coverage across detailed for substantial proportion all patients in England. The following results are preliminary....
Abstract The frequency of, and risk factors for, long COVID are unclear among community-based individuals with a history of COVID-19. To elucidate the burden possible causes in community, we coordinated analyses survey data from 6907 self-reported COVID-19 10 UK longitudinal study (LS) samples 1.1 million diagnostic codes electronic healthcare records (EHR) collected by spring 2021. Proportions presumed cases LS reporting any symptoms for 12+ weeks ranged 7.8% 17% (with 1.2 to 4.8%...
SummaryBackgroundWhether HIV infection is associated with risk of death due to COVID-19 unclear. We aimed investigate this association in a large-scale population-based study England.MethodsWe did retrospective cohort study. Working on behalf NHS England, we used the OpenSAFELY platform analyse routinely collected electronic primary care data linked national registrations. included all adults (aged ≥18 years) alive and follow-up Feb 1, 2020, at least 1 year continuous registration general...
<h2>Summary</h2><h3>Background</h3> COVID-19 has disproportionately affected minority ethnic populations in the UK. Our aim was to quantify differences SARS-CoV-2 infection and outcomes during first second waves of pandemic England. <h3>Methods</h3> We conducted an observational cohort study adults (aged ≥18 years) registered with primary care practices England for whom electronic health records were available through OpenSAFELY platform, who had at least 1 year continuous registration start...
The SARS-CoV-2 B.1.1.7 variant of concern (VOC) is increasing in prevalence across Europe. Accurate estimation disease severity associated with this VOC critical for pandemic planning. We found increased risk death compared non-VOC cases England (hazard ratio: 1.67; 95% confidence interval: 1.34–2.09; p < 0.0001). Absolute by 28 days age and comorbidities. This has potential to spread faster higher mortality than the date.
The risk of severe COVID-19 outcomes in people with immune-mediated inflammatory diseases and on immune-modifying drugs might not be fully mediated by comorbidities vary factors such as ethnicity. We aimed to assess the adults those therapies.
Abstract Objective To compare the effectiveness of sotrovimab (a neutralising monoclonal antibody) with molnupiravir (an antiviral) in preventing severe outcomes covid-19 adult patients infected SARS-CoV-2 community and at high risk from covid-19. Design Observational cohort study OpenSAFELY platform. Setting With approval NHS England, a real world was conducted OpenSAFELY-TPP platform secure, transparent, open source software for analysis electronic health records), patient level record...
Blended learning is a combination of online and face-to-face increasingly interest for use in undergraduate medical education. It has been used to teach clinical post-graduate students pharmacology but needs evaluation its teaching students, which represent different group with needs. An existing BSc-level module on neuropharmacology was redesigned using the Learning Design Tool (BLEnDT), tool uses domains (psychomotor, cognitive affective) classify outcomes into those taught best by...
Background Long COVID describes new or persistent symptoms at least 4 weeks after onset of acute COVID-19. Clinical codes to describe this phenomenon were recently created. Aim To the use long-COVID codes, and variation by general practice, demographic variables, over time. Design setting Population-based cohort study in English primary care. Method Working on behalf NHS England, OpenSAFELY data used encompassing 96% population between 1 February 2020 25 May 2021. The proportion people with...
Abstract Objective To assess the association between learning disability and risk of hospital admission death from covid-19 in England among adults children. Design Population based cohort study on behalf NHS using OpenSAFELY platform. Setting Patient level data were obtained for more than 17 million people registered with a general practice that uses TPP software. Electronic health records linked Office National Statistics Secondary Uses Service. Participants Adults (aged 16-105 years)...
Objectives To assess the association between routinely prescribed non-steroidal anti-inflammatory drugs (NSAIDs) and deaths from COVID-19 using OpenSAFELY, a secure analytical platform. Methods We conducted two cohort studies 1 March to 14 June 2020. Working on behalf of National Health Service England, we used routine clinical data in England linked death data. In study 1, identified people with an NSAID prescription last 3 years general population. 2, rheumatoid arthritis/osteoarthritis....
Abstract Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) alpha variant (B.1.1.7) is associated with higher transmissibility than wild-type virus, becoming the dominant in England by January 2021. We aimed to describe severity of terms pathway disease from testing positive hospital admission and death. Methods With approval NHS England, we linked individual-level data primary care SARS-CoV-2 community testing, admission, Office for National Statistics all-cause...
Abstract Background On December 8th 2020, NHS England administered the first COVID-19 vaccination as part of an ambitious programme during a global health emergency. Aims To describe trends and variation in vaccine coverage by key clinical demographic groups; to create framework for near-real-time monitoring subgroups. Methods Working on behalf we analysed 57.9 million patient records situ within infrastructure Electronic Health Record (EHR) software vendors EMIS TPP using OpenSAFELY. We...
Abstract Objective To investigate whether risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and outcomes disease 2019 (covid-19) differed between adults living without children during the first two waves UK pandemic. Design Population based cohort study, on behalf NHS England. Setting Primary care data pseudonymously linked hospital intensive admissions death records from England, wave 1 (1 February to 31 August 2020) September 18 December 2020)....
Residents in care homes have been severely impacted by COVID-19. We describe trends the mortality risk among residents of compared to private homes. On behalf NHS England we used OpenSAFELY-TPP calculate monthly age-standardised risks death due all causes and COVID-19 adults aged >=65 years between 1/2/2019 31/03/2021. Care home were identified using linkage Quality Commission data. included 4,340,648 people 65 or older on 1st February 2019, 2.2% whom classified as residing a nursing home....
On 8 December 2020 NHS England administered the first COVID-19 vaccination.To describe trends and variation in vaccine coverage different clinical demographic groups 100 days of rollout.With approval England, a cohort study was conducted 57.9 million patient records general practice situ within infrastructure electronic health record software vendors EMIS TPP using OpenSAFELY.Vaccine across various subgroups Joint Committee on Vaccination Immunisation (JCVI) priority cohorts is described.A...
To estimate waning of covid-19 vaccine effectiveness over six months after second dose.
Background There is concern about medium to long-term adverse outcomes following acute Coronavirus Disease 2019 (COVID-19), but little relevant evidence exists. We aimed investigate whether risks of hospital admission and death, overall by specific cause, are raised discharge from a COVID-19 hospitalisation. Methods findings With the approval NHS-England, we conducted cohort study, using linked primary care data in OpenSAFELY compare between people discharged hospitalisation (February...
Abstract Infection with SARS-CoV-2 is associated an increased risk of arterial and venous thrombotic events, but the implications vaccination for this are uncertain. With approval NHS England, we quantified associations between COVID-19 diagnosis cardiovascular diseases in different variant eras using linked electronic health records ~40% English population. We defined a ‘pre-vaccination’ cohort (18,210,937 people) wild-type/Alpha (January 2020-June 2021), ‘vaccinated’ ‘unvaccinated’ cohorts...
Some studies have shown that the incidence of type 2 diabetes increases after a diagnosis COVID-19, although evidence is not conclusive. However, effects COVID-19 vaccine on this association, or effect other subtypes, are clear. We aimed to investigate association between and 2, 1, gestational non-specific diabetes, COVID- 19 vaccination, up 52 weeks diagnosis.